Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New study suggests that having COVID-19 increases a person’s risk of developing psychiatric disorders, and that having a psychiatric disorder increases the chance of getting COVID-19. The study, published in The Lancet Psychiatry, used the TriNetX electronic health records of 69 million people in the USA including over 62,000 cases of COVID-19.

Facemask and open lock with lockdown written on it and a world map etched into it.

Researchers at the University of Oxford, Department of Psychiatry and NIHR Oxford Health Biomedical Research Centre, report the first large-scale evidence that COVID-19 survivors are at an increased risk of psychiatric disorders. 

  • Almost 1 in 5 people diagnosed with COVID-19 receive a psychiatric diagnosis within the next 3 months
  • 1 in 4 of these people had not had a psychiatric diagnosis before COVID-19
  • Patients with existing psychiatric disorders might be more likely to get COVID-19

In the 3 months following testing positive for COVID-19, 1 in 5 survivors were found to get a diagnosis of anxiety, depression, or insomnia, for the first time. This is about twice as likely as for other groups of patients over the same period. A diagnosis of dementia may also be commoner. COVID-19 was also associated with more new psychiatric diagnoses in people who already had a history of psychiatric problems. Overall, almost 20 per cent of people received a psychiatric diagnosis within 90 days of getting COVID-19. 

The full story is available on the Department of Psychiatry website

 

 

Similar stories

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.